Axsome Therapeutics (AXSM) Reports Prelim Q4 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
January 4, 2024 7:00 AM ESTPreliminary total 4Q and full year 2023 net product revenue of $71 million and $204 million, respectively
Auvelity preliminary 4Q and full year 2023 net product sales of $49 million and $130 million, respectively
Sunosi preliminary 4Q and full year 2023 net product revenue of $22 million and $74 million, respectively
2024 anticipated regulatory milestones include NDA submission for AXS-14 in fibromyalgia and NDA resubmission for AXS-07 in migraine
2024 anticipated clinical trial readouts include topline results of the SYMPHONY trial in narcolepsy, ADVANCE-2 trial in Alzheimers disease agitation, and... More
